Prelude Capital Management, LLC Avadel Pharmaceuticals PLC Transaction History

Prelude Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$9.64 - $14.59 $116,412 - $176,188	12,076 New	12,076 $170,000
Q1 2021 May 17, 2021	SELL	$6.61 - $10.07 $337,889 - $514,758	-51,118 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$5.03 - $7.95 $257,123 - $406,388	51,118 New	51,118 $341,000
Q3 2020 Nov 16, 2020	SELL	$5.02 - $8.98 $104,491 - $186,918	-20,815 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$7.25 - $11.75 $150,908 - $244,576	20,815 New	20,815 $168,000
Q4 2017 Feb 14, 2018	SELL	$8.03 - $11.25 $55,406 - $77,625	-6,900 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$8.35 - $10.5 $57,615 - $72,450	6,900	6,900 $72,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.